Genzyme asks FDA to expand clofarabine's use to adults

11/24/2008 | American City Business Journals

Genzyme submitted an application seeking FDA approval to market clofarabine to treat adults with acute myeloid leukemia. The biotech firm already sells the drug under the brand Clolar for relapsed and treatment-resistant patients between ages 1 and 21 who suffer from acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ